<DOC>
	<DOCNO>NCT02629094</DOCNO>
	<brief_summary>Background : People human immunodeficiency virus ( HIV ) high risk get visceral deep belly fat . Visceral fat cause health problem like heart liver disease . Researchers want see blood pressure drug help block hormone body . Objective : To see eplerenone reduces fat store heart muscle liver people HIV increase visceral fat . Eligibility : Adults age 18 75 HIV increase waist circumference . Increased waist circumference define 40 inch men 35 inch woman . Design : Participants screen : Physical exam Medical history Blood test Measurements hip , waist , leg , arm , shoulder , neck Magnetic resonance imaging ( MRI ) scan . They lie table slide machine . Electrocardiogram ( EKG ) measure heart electrical activity Transient elastography , special ultrasound measure liver tissue stiffness A small piece liver collect ( optional ) Participants baseline visit : Physical exam Medical history Blood test DEXA scan measure body fat , muscle mass , bone density . Participants lie table small dose x-rays go body . Resting energy expenditure ( REE ) . This measure amount oxygen breathe carbon dioxide breathe . Participants get 1-week supply eplerenone . They take one pill per day . Participants follow-up visit 1 week later . They : Physical exam Medical history Blood test 23-week supply eplerenone Participants 5 follow-up visit . Participants final study visit , repeat many screen baseline test .</brief_summary>
	<brief_title>Cardiometabolic Effects Eplerenone HIV Infection</brief_title>
	<detailed_description>HIV-infected individual high risk uninfected people develop cardiovascular disease . Visceral adipose tissue also increase HIV-infected people compare uninfected individual . Animal study suggest blockade mineralocorticoid receptor ( MR ) may beneficial effect cardiovascular metabolic parameter via inhibition adipocyte differentiation triglyceride accumulation . We examine effect MR antagonist eplerenone ( 50 mg daily ) HIV-infected adult abdominal fat accumulation 24-week , open-label , proof-of-concept study . Magnetic resonance imaging conduct screen final study visit evaluate cardiac hepatic steatosis . We anticipate block effect increase aldosterone secretion eplerenone significantly reduce intramyocardial lipid content hepatic steatosis population . These effect may accompany decrease visceral adipose tissue , improvement dyslipidemia inflammation , thereby improve cardiovascular health .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Increased waist circumference basis National Cholesterol Education Program guideline ( &gt; 102 cm men &gt; 88 cm woman ) 2 . Hepatic steatosis establish hepatic MRI great equal 5 % and/or liver biopsy within last 12 month 3 . HIVinfected , HIV viral load &lt; 50 copies/mL change ART regimen least 3 month 4 . Age great equal 18 less equal 75 year 5 . Agree sample store future research EXCLUSION CRITERIA : 1 . Estimated glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m^2 , serum creatinine &gt; 1.5 mg/dL 2 . Serum potassium &gt; 5.5 mEq/L , alanine aminotransferase &gt; 2.5 time upper limit normal , hemoglobin ( Hgb ) &lt; 11 g/dL 3 . Uncontrolled hypertension : systolic blood pressure great equal 160 mm Hg diastolic blood pressure great equal 100 mm Hg 4 . A blood pressure &lt; 90mmHg systolic &lt; 50mm Hg diastolic 5 . Screening EKG significant heart block ( e.g . PR &gt; 300 m ) EKG determine significant Cardiology consult . 6 . Current hepatitis C infection , unless sustain virologic response least 12 month 7 . Type 2 diabetes microalbuminuria 8 . Current prior steroid use within past 6 month ( except shortcourse singledose administration ) . Stable use inhale nasal steroid allow . 9 . Use angiotensin convert enzyme ( ACE ) inhibitor , angiotensin reporter blocker ( ARBs ) , potassiumsparing diuretic , medication may increase risk hyperkalemia 10 . Use potassium supplementation medication know increase potassium 11 . Concomitant use strong inhibitor and/or inducer ofof cytochrome P450 isozyme ( CYP ) 3A4 12 . If receive testerone , estrogen progesterone therapy , must stable dose least 3 month . 13 . Current use growth hormone growth hormonereleasing hormone 14 . Current serious viral , bacterial , infection ( exclude HIV ) 15 . Current active substance abuse/dependence 16 . Substantial history cardiovascular disease , include prior myocardial infarction ( MI ) , congestive heart failure , stroke 17 . Contraindication MRI 18 . Pregnant plan become pregnant 19 . Breastfeeding 20 . Any condition , opinion PI , may substantially increase risk participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 8, 2017</verification_date>
	<keyword>Hepatic Steatosis</keyword>
	<keyword>Cardiac Steatosis</keyword>
	<keyword>Aldosterone</keyword>
	<keyword>Eplerenone</keyword>
	<keyword>Mineralcorticoid Receptor</keyword>
</DOC>